Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Therapeutics Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NES-ZIONA, ISRAEL, DEC. 04, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, ENLIVEX OR THE COMPANY), TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL FIRESIDE CHAT ON THURSDAY, DECEMBER 11, 2025 AT 11:00 AM ET.

ENLIVEX MANAGEMENT TO HOST FIRESIDE CHAT ON DECEMBER 11 TO DISCUSS RAIN TOKEN STRATEGY AND ALLOCETRA CLINICAL DEVELOPMENT

ENLIVEX ANNOUNCED TODAY $212,000,000 PRIVATE PLACEMENT TO INITIATE WORLD'S FIRST PREDICTION MARKETS DIGITAL ASSET TREASURY STRATEGY, VIA RAIN TOKEN ACCUMULATION NESSZIONA, ISRAEL , NOV. 24, 2025 /PRNEWSWIRE/ -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV) TODAY ANNOUNCED THE APPOINTMENT OF MR.

ENLIVEX APPOINTS FORMER ITALY PRIME MINISTER MATTEO RENZI TO BOARD OF DIRECTORS

- UPON THE CLOSING OF THE PRIVATE PLACEMENT, ENLIVEX WILL ADOPT THE WORLD'S FIRST RAIN PREDICTION MARKETS TOKEN DIGITAL ASSET TREASURY STRATEGY, VIA RAIN TOKEN ACCUMULATION. - RAIN IS A FULLY DECENTRALIZED PREDICTIONS AND OPTIONS PROTOCOL THAT REDEFINES PREDICTIVE MARKET ECOSYSTEMS AND PROVIDES A POWERFUL PLATFORM FOR ON-CHAIN MARKET CREATION - BUILT FOR TRANSPARENCY, AUTOMATION, AND COMMUNITY PARTICIPATION.

ENLIVEX ANNOUNCES $212,000,000 PRIVATE PLACEMENT TO INITIATE WORLD'S FIRST PREDICTION MARKETS DIGITAL ASSET TREASURY STRATEGY, VIA RAIN TOKEN ACCUMULATION, AND THE APPOINTMENT OF MATTEO RENZI, FORMER PRIME MINISTER OF ITALY, TO ITS BOARD

NES-ZIONA, ISRAEL, NOV. 24, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. ( NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED POSITIVE SIX-MONTH EFFICACY DATA FROM THE PHASE IIA STAGE OF ITS RANDOMIZED, MULTI-COUNTRY PHASE I/II ALLOCETRA TRIAL (ENX-CL-05-001) IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS (OA). THE SIX-MONTH FOLLOW-UP HAS NOW BEEN COMPLETED FOR ALL PATIENTS. THE RESULTS RE-AFFIRM THE THREE-MONTH DATA REPORTED PREVIOUSLY AND SUBSTANTIATE THE IDENTIFICATION OF AN AGE-RELATED PRIMARY OA RESPONDER POPULATION.

ENLIVEX ANNOUNCES POSITIVE 6-MONTH TOPLINE DATA DEMONSTRATING DURABLE AND PERSISTENT PAIN REDUCTION AND IMPROVED FUNCTION IN PRIMARY AGE-RELATED PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS

NESS-ZIONA, ISRAEL, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER ABSTRACT AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE OCTOBER 2429 AT MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

ENLIVEX THERAPEUTICS TO PRESENT PHASE IIA 3-MONTH DATA OF ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS AT THE ACR CONVERGENCE 2025

NES-ZIONA, ISRAEL, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, WILL PARTICIPATE IN A LIVE INVESTOR WEBINAR, ADVANCING INFLAMMATORY DISEASE TREATMENT: INSIGHTS & BREAKTHROUGHS FROM ENLIVEX'S KNEE OSTEOARTHRITIS PROGRAM, HOSTED BY D. BORAL CAPITAL ON SEPTEMBER 30, 2025, AT 10:00 AM EASTERN TIME. THE DISCUSSION WILL BRING TOGETHER LEADING KEY OPINION LEADERS (KOLS) IN MUSCULOSKELETAL DISEASE, ALONGSIDE ENLIVEX'S VICE CHAIRMAN AND D. BORAL'S RESEARCH DIRECTOR.THE SEPTEMBER 30 KOL WEBINAR WILL EXPLORE RECENT BREAKTHROUGHS IN TREATMENT APPROACHES DISCUSSING THE POSITIVE PHASE IIA TOPLINE DATA FROM ENLIVEX'S ALLOCETRA PROGRAM IN MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS (KOA) PATIENTS. DATA DEMONSTRATED CLINICALLY MEANINGFUL AND HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN PAIN AND IMPROVEMENTS IN FUNCTION IN IDIOPATHIC, AGE-RELATED KNEE OSTEOARTHRITIS PATIENTS, A LARGE, UNDERSERVED POPULATION.

D. BORAL CAPITAL TO HOST KOL WEBINAR WITH WORLD LEADING EXPERTS FEATURING INSIGHTS & BREAKTHROUGHS FROM ENLIVEX'S KNEE OSTEOARTHRITIS PROGRAM

ALLOCETRA DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PAIN AND FUNCTION IN PHASE IIA TRIAL IN PRIMARY OSTEOARTHRITIS PATIENTS    SIX-MONTH DATA EXPECTED NOVEMBER 2025; PHASE IIB TRIAL INITIATION PLANNED FOR Q2 2026 NES-ZIONA, ISRAEL, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD.

ENLIVEX CEO ISSUES LETTER TO SHAREHOLDERS OUTLINING STRATEGIC ROADMAP FOLLOWING POSITIVE PHASE IIA ALLOCETRA RESULTS

NES-ZIONA, ISRAEL, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD.

ENLIVEX ANNOUNCES ISSUANCE OF NEW PATENT APPLICATION COVERING THE USE OF ALLOCETRA IN PATIENTS WITH OSTEOARTHRITIS

ENX-CL-05-001 TRIAL: 3-MONTHS TOPLINE DATA -IN THE OVERALL MODIFIED INTENTION-TO-TREAT (MITT) POPULATION, IMPROVEMENTS ACROSS ALL EFFICACY AND SECONDARY ENDPOINTS, INCLUDING 24% REDUCTION IN KNEE PAIN AND 26% IMPROVEMENT IN KNEE FUNCTION, WERE OBSERVED IN THE ALLOCETRATM TREATMENT ARM VS PLACEBO; MOREOVER, 72% REDUCTION IN KNEE PAIN AND 95% IMPROVEMENT IN KNEE FUNCTION WERE OBSERVED FOR AGE-RELATED PRIMARY OSTEOARTHRITIS PATIENTS COMPARED WITH PLACEBO  A SUBSTANTIAL, CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT EFFECT IN COMMONLY USED PHASE III PRIMARY ENDPOINTS FOR KNEE OSTEOARTHRITIS CLINICAL TRIALS. -FAVORABLE SAFETY PROFILE  NO SEVERE ADVERSE EVENTS; LIMITED, TYPICALLY MILD TO MODERATE, TRANSIENT, AND TREATABLE SIDE EFFECTS OCCURRED IN MOST PATIENTS TREATED WITH ALLOCETRA -WEBINAR TODAY AT 8:00 A.M.

ENLIVEX ANNOUNCES POSITIVE TOPLINE DATA FROM MULTI-COUNTRY, RANDOMIZED, CONTROLLED, PHASE I/II TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS

WEBINAR TO REVIEW RESULTS FROM MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ALLOCETRA IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS NES-ZIONA, ISRAEL, AUG. 14, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED IT WILL HOST AWEBINAR ON MONDAY, AUGUST 18, 2025, AT 8:00 AM EASTERN TIME TO PRESENT AND DISCUSS 3-MONTH TOPLINE RESULTS FROM THE PHASE IIA STAGE OF ITS PHASE I/IIA ENX-CL-05-001 TRIAL, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTI-CENTERED STUDY.

Enlivex Therapeutics Ltd.

ENLV

Price

Financial Reports

No items found.

Press Releases

Enlivex Therapeutics Ltd.

ENLV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ENLV